The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IND.210: A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC).
 
Patricia A. Tang
Consulting or Advisory Role - Amgen; Celgene; Genomic Health; Roche Canada; Sanofi
 
Derek J. Jonker
No Relationships to Disclose
 
Hagen F. Kennecke
No Relationships to Disclose
 
Stephen Welch
Honoraria - Amgen; Celgene; Roche; Sanofi
Consulting or Advisory Role - Amgen; Roche
Research Funding - Amgen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Roche
 
M. Christine Cripps
No Relationships to Disclose
 
Timothy R. Asmis
No Relationships to Disclose
 
Haji I. Chalchal
No Relationships to Disclose
 
Anna T. Tomiak
No Relationships to Disclose
 
Yoo-Joung Ko
No Relationships to Disclose
 
Eric Chen
No Relationships to Disclose
 
Thierry Alcindor
Honoraria - Amgen; Lilly; Sanofi
 
John R. Goffin
Consulting or Advisory Role - Amgen; Boehringer Ingelheim
 
Ashley Theis
No Relationships to Disclose
 
George M. Gill
Leadership - Oncolytics
 
Dongsheng Tu
No Relationships to Disclose
 
Lesley Seymour
Stock and Other Ownership Interests - AstraZeneca
Honoraria - Innate Pharma
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)